Breaking News

Financial Report: Sanofi 2Q11

Generic competition hits Lovenox and Taxotere, Genzyme sales up 16%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi 2Q11 2Q Revenues: $12.0 billion (+1%) 2Q Earnings: $3.0 billion (-13%) YTD Revenues: $23.2 billion (-1%) YTD Earnings: $6.2 billion (-12%) Note: All percentage-changes based on local currency Comments: Pharmaceutical sales were $10.3 billion  (+2%). Excluding Genzyme’s $1.1 billion contribution, sales were down 4%, a result of generic competition for Lovenox (-35%) and Taxotere (-65%). Diabetes sales were up 12% driven by Lantus (+15%) and Apidra (+30%). Genzyme revenues were up 16%...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters